Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma
NCT02933736Phase 1Active, not recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- Oct 2016
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in glioblastoma multiforme (GBM) and meningioma, sponsored by Ivy Brain Tumor Center. Primary endpoints: Plasma Exposure of Ribociclib, Cerebrospinal Fluid Penetration of Ribociclib and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
glioblastoma multiforme (GBM)meningioma
Beyond the preview
Go deeper on NCT02933736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933736.